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Abstract
Background: Pregnancy-associated plasma protein A2 (PAPPA2) is an insulin-like growth factor-binding protein
(IGFBP) protease expressed at high levels in the placenta and upregulated in pregnancies complicated by
preeclampsia and HELLP (Hemolytic anemia, Elevated Liver enzymes, and Low Platelet count) syndrome. However,
it is unclear whether elevated PAPPA2 expression causes abnormal placental development, or whether
upregulation compensates for placental pathology. In the present study, we investigate whether PAPPA2
expression is affected by hypoxia, oxidative stress, syncytialization factors or substances known to affect the
expression of PAPPA2’s paralogue, PAPPA.
Methods: BeWo cells, a model of placental trophoblasts, were treated with one of the following: hypoxia (2% O2),
oxidative stress (20 microM hydrogen peroxide), forskolin (10 microM and 100 microM), TGF-beta (10 and 50 ng/mL),
TNF-alpha (100 ng/mL), IL-1beta (100 ng/mL) or PGE2 (1 microM). We used quantitative RT-PCR (qRT-PCR) to quantify
the mRNA levels of PAPPA2, as well as those of PAPPA and ADAM12 since these proteases have similar substrates and
are also highly expressed in the placenta. Where we observed significant effects on PAPPA2 mRNA levels, we tested for
effects at the protein level using an in-cell Western assay.
Results: Hypoxia, but not oxidative stress, caused a 47-fold increase in PAPPA2 mRNA expression, while TNF-alpha
resulted in a 6-fold increase, and both of these effects were confirmed at the protein level. PGE2 resulted in a
14-fold upregulation of PAPPA2 mRNA but this was not reflected at the protein level. Forskolin, TGF-beta and
IL-1beta had no significant effect on PAPPA2 mRNA expression. We observed no effects of any treatment on
PAPPA or ADAM12 expression.
Conclusion: Our study demonstrates that factors previously known to be highly expressed in preeclamptic
placentae (PGE2 and TNF-alpha), contribute to the upregulation of PAPPA2. Hypoxia, known to occur in
preeclamptic placentae, also increased PAPPA2 expression. These results are consistent with the hypothesis that
PAPPA2 is upregulated as a consequence of placental pathology, rather than elevated PAPPA2 levels being a cause
of preeclampsia.
Background
Preeclampsia affects approximately 1 in 15 pregnancies [1]
and is characterized by a sudden rise in blood pressure
and proteinuria which resolves after delivery [2,3].
Currently, there is no effective treatment for preeclampsia
other than to induce delivery. However, premature deliv-
ery elevates the risk of neonatal death and health problems
later in life [3-5]. The etiology of preeclampsia is thought
to involve abnormal placental development [6-8].
Numerous studies have attempted to elucidate the
mechanisms underlying abnormal placental development
using microarrays to identify genes differentially
expressed between placentae from healthy and compli-
cated pregnancies [9,10]. Five studies have shown that
placental expression of pregnancy-associated plasma pro-
tein A2 (PAPPA2) is upregulated at delivery in pree-
clampsia or a complication of preeclampsia, HELLP
(Hemolytic anemia, Elevated Liver enzymes, and Low
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insulin-like growth factor-binding protein (IGFBP) pro-
tease [15] expressed at high levels during pregnancy
[16,17] which shares approximately 40% amino acid simi-
larity with PAPPA [15]. Abnormally low PAPPA levels in
first trimester maternal circulation are associated with
increased risk of preeclampsia [18,19], a pattern also
observed for another IGFBP protease, ADAM12 [19-23].
It is not known whether altered PAPPA2 expression
causes preeclampsia or is a response to placental pathol-
ogy. It has been hypothesized that the upregulation of
PAPPA2 in preeclamptic pregnancies is a compensatory
response to abnormal placentation which might increase
IGF availability and promote feto-placental growth [18].
A number of factors might trigger this upregulation,
and in the present study we attempt to identify factors
that regulate PAPPA2 expression.
Early placental development takes place in a low-oxygen
environment [24], but impaired invasion into the decidua
is thought to lead to even lower oxygen levels (hypoxia) in
preeclampsia [1,10,25-27], which we hypothesize could
upregulate PAPPA2. Ischemia-reperfusion injury might
also occur due to intermittent blood flow into the intervil-
lous spaces of the placenta [28], leading to the formation
of damaging reactive oxygen species (ROS); this oxidative
stress can be mimicked by peroxides [25,28,29].
It has been suggested that improper trophoblast cell
fusion, or syncytialization, may be a cause of preeclampsia
[6]. Since PAPPA2 is expressed in the syncytiotrophoblast
[14,17], we hypothesize that factors that affect syncytializa-
tion [30-32] will affect PAPPA2 expression.
The paralog of PAPPA2, PAPPA, is upregulated by
TNF-a, TGF-b, PGE2, and IL-1b in osteoblasts [33], and
we predict that these factors may also regulate PAPPA2
expression, given the homology between PAPPA and
PAPPA2.
The goal of the present study was to test our hypotheses
regarding the regulation of PAPPA2 using BeWo cells as a
model of placental trophoblasts [34,35]. In addition to
PAPPA2, we also measured levels of PAPPA and
ADAM12 since they are also placental IGFBP proteases
[21,36] associated with preeclampsia and intrauterine
growth restriction (IUGR) [19,22,23,37,38], and IGFBP
proteases may be coregulated [39]. We also measured
levels of E-cadherin mRNA to determine the level of
syncytialization, since E-cadherin expression decreases as
cells fuse [40].
Methods
Cell culture and materials
BeWo cells, a gift from Dr. Andrée Gruslin of the
University of Ottawa, were cultured in Ham’sF - 1 2 K
medium (Sigma Aldrich, St. Louis, MO) supplemented
with 10% fetal bovine serum, 2 mM L-glutamine,
100 U/mL penicillin and 100 U/mL streptomycin in 5%
CO2 and 95% air at 37°C. Cells were used at passages
30-42. Porcine TGF-b, recombinant TNF-a, and recom-
binant IL-1b were purchased from R&D Systems
(Minneapolis, MN), forskolin and PGE2 were purchased
from Sigma (St. Louis, MO), and 3% w/v H2O2 was
purchased from Anachemia (Lachine, Quebec).
Experimental treatments
For the hypoxic treatment, cells were cultured in 9 cm
plates at 30% confluence and were maintained at 37°C in
5% CO2 and 95% air (normoxia) for 24 h, at which time
the cells had reached 50% confluence. Half of the plates
(N = 5) remained under normoxic conditions while the
other half were transferred to a chamber with an atmo-
sphere of 93% N2,5 %C O 2, and 2% O2, as used previously
to simulate hypoxia during preeclampsia [31,41,42]. These
plates were incubated for a further 24h before protein
analysis or collection for RNA isolation.
For the growth factor and peroxide treatments, cells
were cultured under normoxic conditions as described
above for 24 h. The medium was then replaced with
fresh medium (control samples) or medium containing
H2O2 at 20 μM [29] or one of the following factors pre-
viously shown to upregulate PAPPA in osteoblasts cells:
TGF-b (10 ng/mL and 50 ng/mL), TNF-a (100 ng/mL)
IL-1b (100 ng/mL), prostaglandin E2 (1 μM), forskolin
(10 μM and 100 μM, each dissolved in 0.1% ethanol) or a
forskolin control (medium with 0.1% ethanol only)
[30,32,33,43] (N = 5 plates per treatment).
Cell counting
BeWo cells were cultured on 6-well plates for 24 hours,
with the treatments described above. 2 μLo fH o e c h s t
33342 (Invitrogen, Carlsbad, CA) was added (final con-
centration of 1.5 μg/mL), and the plates were incubated
for 20 minutes at 37°C. The medium was then replaced
with 2 mL of Hank’s buffered salt solution (HBSS). Five
pictures were taken of each well at 10x magnification,
and cells were counted using ImageJ software (NIH).
Each experiment was repeated three times.
RNA isolation and RT-PCR
BeWo cells were collected and homogenized in 600 μL
of buffer RLT (Qiagen, Ontario, Canada) using pipetting
and Qiashredders (Qiagen, Ontario, Canada) and total
RNA was extracted using the RNeasy Mini kit (Qiagen,
Ontario, Canada) according to the manufacturer’s
instructions. RNA concentration was determined using a
Nanodrop spectrophotometer (Thermo Fischer Scientific
Inc. Waltham, MA), and each sample was diluted to a
final concentration of 50 ng/μL. Reference samples were
made by combining 50 μL from each sample. These
reference samples were measured for each gene and
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between assays. Quantitative reverse transcriptase PCR
(qRT-PCR) was performed to compare levels of
PAPPA2, PAPPA, ADAM12, and E-cadherin mRNA.
Levels of b-actin [31] and GAPDH [44] were also mea-
sured and used to standardize the values of the other
genes (see Table 1 for primer sequences). The qScript
one-step SYBR green qRT-PCR kit (Quanta Biosciences
Inc. Gaithersburg, MD) was used to reverse-transcribe
and amplify each sample. Reverse transcription was
carried out at 50°C for 30 minutes, followed by a PCR
activation step of 95°C for 15 minutes, followed by
amplification by 40 cycles of 1 minute at 94°C, 1 minute
at either 50°C, 56°C or 60°C (see Table 1 for annealing
temperatures for each gene), and 1 minute at 72°C, and
a final extension of 10 minutes at 72°C. Each reaction
was performed using a volume of 25 μL and contained
12.5 μL of reaction mix, 8.5 μLo fR N As a m p l ea t
50 ng/μL, 1.5 μL (22.5 mM) of each forward and reverse
primer, 0.5 μL of reverse transcriptase, and 0.5 μLo f
nuclease free water. Ct values were recorded for each
gene, defined as the point at which the signal crossed a
predetermined threshold. Each sample was measured in
triplicate and in each assay, one negative control and
one reference sample were included for each gene. For
each gene, we performed a melting curve analysis, and
the qRT-PCR products were run on a 1% agarose gel to
ensure that only one amplicon of the expected size was
present.
In-cell Westerns
In-cell Westerns, an immunocytochemical assay to quan-
tify proteins in fixed cells [45], were performed for treat-
ments which had a significant effect on PAPPA2 mRNA
levels (2% O2,1μMP G E 2, 100 ng/mL TNF-a). Cells were
cultured on 6-well plates, and treatments were performed
as described above, using three wells per treatment
(N = 3). Following treatment, the medium was removed,
and the cells were fixed in 2.4 mL of 3.7% formaldehyde in
PBS for 20 min. The cells were then permeabilized by
washing with 3.2 mL PBS containing 0.1% Triton X-100
(Sigma Aldrich, St. Louis, MO) 5 times for 5 minutes
each, with gentle shaking. The cells were blocked using
2.4 mL of near infrared blocking buffer (Rockland,
Gilbertsville, PA) for 1.5 h with gentle shaking. The cells
were then incubated overnight at 4°C with 1:200 goat anti-
human PAPPA2 polyclonal (AF1668; R&D Systems,
Minneapolis, MN) and 1:200 mouse anti-tubulin (T9026,
Sigma, St Louis, MO) antibodies diluted in blocking buffer
(Li-Cor Biosciences, Lincoln, NE) and 0.1% Tween-20
(Sigma, ON, Canada) with gentle shaking, followed by
5 washes with PBS and 0.1% Tween-20 for 5 minutes per
wash. Incubation with the secondary antibodies was
carried out using a solution containing 1:800 fluores-
cently-labelled IRDye 800 donkey anti-goat and IRDye
680 donkey anti-mouse secondary antibodies (Li-Cor
Biosciences, Lincoln, NE) diluted in Odyssey Blocking
Buffer and 0.1% Tween-20 for 1 h in the dark with gentle
shaking. We performed 5 more 5 minute washes with PBS
in the dark to prevent breakdown of the IR dye. All steps
except for primary antibody incubations were performed
at room temperature. Two negative controls were
included, one omitting each primary antibody. Preliminary
work showed that the PAPPA2 and tubulin signals were
above negative controls under control conditions. We
used tubulin to standardize the amount of cells in each
well because we were unable to detect a strong signal
using an anti-actin antibody (CLT9001; Cedarlane,
Burlington ON). The intensity of staining in cells was
quantified by densitometry using an Odyssey infrared
imaging system (Li-Cor Biosciences).
Western Blot
Cell cultured medium was centrifuged to remove cellular
debris, and 40 μL was mixed with 5x SDS loading buffer
and heated for 10 minutes at 100°C. Samples were run for
60 minutes through a 4% stacking and 8% separating poly-
acrylamide gel. After transfer, nitrocellulose membranes
were blocked for 1 hour at room temperature in infrared
blocking buffer, then incubated in 1:500 polyclonal goat
anti-human PAPPA2 antibody diluted in the same block-
ing buffer, with 0.1% Tween-20. Membranes were washed
4 times in filter-sterilized PBS containing 0.1% Tween-20
at room temperature, and incubated in a solution contain-
ing 1:10000 fluorescently-labelled IRDye 800 secondary
antibody diluted in blocking buffer, 0.1% Tween-20 and
0.1% SDS for 45 minutes in the dark with gentle shaking.
The membranes were again washed 4 times for 5 minutes
Table 1 Primer and probe sequences used in qRT-PCR for PAPPA2, PAPPA, ADAM12, E-cadherin, b-actin and GAPDH
Gene Forward Primer Reverse Primer Annealing Temperature Source
PAPPA2 ACTCACCCAAGAGGGCATACATGA GCACTGAGCTGGCAAAGTAGATGT 50°C This paper
PAPPA GTCATCTTTGCCTGGAAGGGAGAA AGGGCTGTTCAACATCAGGATGAC 56°C This paper
ADAM12 CTGGGCCACAATTTCGGGATGAAT ACTGCTGAACACCATGGGAAATGG 50°C This paper
E-cadherin AGCCTCTGGATAGAGAACGCATTG GGGTGAATTCGGGCTTGTTGTCAT 50°C This paper
b-actin GCGAGAAGATGACCCAGGATC CCAGTGGTACGGCCAGAGG 60°C Knerr et al. (2005) [31]
GAPDH CGGGAAGCTTGTGATCAATGG GGCAGTGATGGCATGGACTG 56°C Kudo et al. (2003) [30]
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room temperature, rinsed with filtered PBS, and scanned
with an Odyssey infrared imaging system.
Statistical analyses
We used the method of Pfaffl [46] to calculate mRNA
expression levels for PAPPA2, PAPPA, ADAM12, and E-
cadherin, relative to the reference sample described
above. For example, a value of 2 indicates a sample has 2
times more transcript than the reference sample, correct-
ing for GAPDH or b-actin. qRT-PCR data were analysed
using Wilcoxon signed-rank tests in JMP, Version 7 (SAS
Institute Inc., Cary, NC). Results were normalized to
b-actin or GAPDH.
Results and Discussion
BeWo cells express PAPPA2, with Ct values of approxi-
mately 25 and signal above the no-primary negative con-
trol in in-cell Western analysis. We examined the mRNA
levels of PAPPA2, PAPPA, ADAM12 and E-cadherin in
BeWo cells treated with different factors known to be
involved in preeclampsia or shown to upregulate PAPPA.
GAPDH and b-actin mRNA levels were used to normalize
the mRNA levels of the other genes. However, GAPDH
has been shown to increase under hypoxia [47], so only
b-actin was used for hypoxia. The mRNA levels of b-actin
and GAPDH did not differ significantly between treat-
ments, suggesting that they were appropriate for use as
controls. When used to standardize mRNA levels, b-actin
and GAPDH produced similar results.
Hoechst 33342 staining was used to assess the number
of BeWo cells under each treatment. Cells with condensed
staining were considered dead, whereas cells with diffuse
signal were considered alive. We did not find any signifi-
cant cell death between treatments, when counting either
the proportion or absolute number of alive and dead cells,
which is consistent with previous studies [29,31].
Hypoxia and oxidative stress
Hypoxia has previously been shown to upregulate several
factors in BeWo cells, including HIF-1 [48,49] and down-
regulate factors such as syncytin [44,50]. We found
PAPPA2 mRNA levels were approximately 47 times
higher when BeWo cells were grown under hypoxic
conditions (Figure 1; Wilcoxon Z = 2.506, p = 0.0122).
We confirmed that this differential expression was
reflected in protein levels, and found an approximate
14% upregulation of PAPPA2 protein using in-cell
Western staining. Western blotting did not detect
PAPPA2 in the conditioned cell medium (data not
s h o w n ) ,e v e nt h o u g hw ew e r ep r e v i o u s l ya b l et od e t e c t
PAPPA2 in Western blots of murine and human tissue
[17,51]. Our inability to measure secreted PAPPA2 may
account for the difference in the magnitude of effect on
mRNA and protein expression. Hypoxia had no signifi-
cant effect on either PAPPA (Wilcoxon Z = 0.4178, p =
0.6761) or ADAM12 (Wilcoxon Z = 0, p = 1) expression.
Impaired trophoblast invasion into the maternal decidua
is thought to cause decreased and intermittent blood
flow to the placenta [25,28,52], with reperfusion leading
to an increase in reactive oxygen species with potentially
damaging effects. A previous study found that addition of
reactive oxygen species, specifically hydrogen peroxide at
high levels (50 uM) caused an increase in apoptosis in
BeWo cells [29]. We therefore used a lower H2O2 con-
centration (20 uM) to mimic reperfusion injury and did
not find any effect on PAPPA2 mRNA expression after
24 hours (Figure 1; Wilcoxon Z = 0.417, p = 0.6761).
Factors that affect syncytialization
TNF-a has been shown to impair syncytialization, based
on impaired expression of hCG [53]. TNF-a expression
has also been shown to increase in preeclamptic pregnan-
cies at delivery [54] and in response to hypoxia/reoxygena-
tion conditions [55]. Treating cells with 100 ng/mL
TNF-a resulted in 6.34 times higher PAPPA2 expression
(Figure 1; Wilcoxon Z = 2.507, p = 0.0122). This upregula-
tion was confirmed using in-cell Western analysis, where
we found an 18% upregulation in PAPPA2 protein expres-
sion compared to controls. Once again, our inability to
detect free PAPPA2 in cell medium may account for the
Figure 1 PAPPA2 mRNA expression in BeWo cells. PAPPA2
mRNA levels are expressed as fold change compared to control
(0.1% ethanol was used as a control for forskolin). Cells were treated
for 24 hours with 10 μM forskolin, 100 μM forskolin, 20 μMH 2O2,
2% O2 (hypoxia), 100 ng/mL IL-1b,1μM PGE2, 10 ng/mL TGF-b,5 0
ng/mL TGF-b, and 100 ng/mL TNF-a, N = 5. Columns with an
asterisk (*) indicate expression significantly different from the control
(p < 0.05). Although the mean 10 ng/mL TGF-b expression is high,
only one of the five replicates showed high expression levels
relative to controls.
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p = 0.5309) and ADAM12 (Z = 0.209, p = 0.8345) mRNA
levels were not found to be affected by treatment with
TNF-a.T G F - b has also been shown to inhibit trophoblast
differentiation in human cytotrophoblast cells [56] perhaps
due, in part, to its proposed tumor-suppressing activity
[57]. We did not find any effect of 10 ng/mL TGF-b or
50 ng/mL TGF-b on PAPPA2 mRNA expression (Figure 1;
Wilcoxon Z = 0, p = 1; Wilcoxon Z = 0.2089 p = 0.8345;
respectively). Treatment with TGF-b did not cause any
significant increase in PAPPA (10 ng/mL Wilcoxon Z =
-0.209, p = 0.8345; 50 ng/mL Z = -0.418, p = 0.6761) or
ADAM12 (10 ng/mL Wilcoxon Z = 0, p = 1; 50 ng/mL
Z = 0, p = 1) mRNA levels. Furthermore, we did not find
any significant difference in E-cadherin expression, sug-
gesting that neither TNF-a (Wilcoxon Z = 0.208, p =
0.8345) nor TGF-b (10 ng/mL Wilcoxon Z = 0.626, p =
0.5309; 50 ng/mL Z = -0.418, p = 0.6761) changed the rate
of syncytialization.
Forskolin has been shown to increase intracellular
cAMP levels and trigger increased cellular fusion in BeWo
cells [30]. Surprisingly, we did not detect a significant
decrease in E-cadherin mRNA compared to the 0.1% etha-
nol vehicle control (10 μM: Wilcoxon Z = -1.880, p =
0.0601; 100 μM: Wilcoxon Z = -1.462, p = 0.1437), and so
did not find significant evidence of syncytialization in
response to forskolin treatment. However, previous studies
have shown that forskolin treatment at both 10 μM [57]
and 100 μM [30,32,44,58] does induce cell fusion, based
on other measurements of syncytialization such as levels
of syncytin and human chorionic gonadotropin (hCG).
We did not find any significant effect of either 10 μMo r
100 μM of forskolin on PAPPA2 expression (Figure 1;
Wilcoxon Z = 0.418, p = 0.6761 in both cases).
Factors known to upregulate PAPPA
A previous study by Conover et al. [33] tested the effect of
various growth factors on PAPPA expression in osteo-
blasts, finding that TGF-b,T N F - a,I L - 1 b or PGE2 all
increased PAPPA mRNA and protein expression. As we
described above, in BeWo cells TGF-b had no effect on
PAPPA2 expression, but TNF-a caused a significant upre-
gulation in both mRNA and protein. Treating BeWo cells
with 100 ng/mL IL-1b did not have a significant effect on
PAPPA2 mRNA expression (Figure 1; Wilcoxon Z = 1.462,
p = 0.1437). In preeclamptic pregnancies, PGE2 levels
increase in placental tissue at term [59], and we found that
treatment with 1 μMP G E 2 resulted in a 14-fold upregula-
tion of PAPPA2 mRNA levels (Figure 1; Wilcoxon Z =
2.507, p = 0.0122). However, we were not able to confirm
PAPPA2 protein upregulation using the in-cell Western
assay. Furthermore, PAPPA and ADAM12 were not
affected by any of these factors, including PGE2 (Z =
-1.6712, p = 0.0947; Z = -1.6712, p = 0.0947; respectively).
Conclusions
Our study demonstrated that factors highly expressed in
preeclamptic patients, PGE2 and TNF-a [54,59], increase
the expression of PAPPA2, at least at the mRNA level,
suggesting a potential mechanism underlying the elevated
PAPPA2 levels in preeclamptic placentae at term
[9,11-14]. Hypoxia, a condition known to occur in pre-
eclamptic placentae [10], was also shown to increase
PAPPA2 expression. However, these same treatments
had no effect on two other IGFBP proteases, PAPPA and
ADAM12. We have previously demonstrated that differ-
ences in placental PAPPA2 expression do not result in
significant changes in placental or birth weight in mice
[51]. Both these previous results and those of the present
study are consistent with the hypothesis that PAPPA2 is
upregulated as a consequence of placental pathology,
rather than elevated PAPPA2 levels being a cause of
abnormal placental development and preeclampsia.
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